Might existing drugs (including olamkicept or sodium–glucose cotransporter 2 (SGLT-2) inhibitors) prove useful as anti-arrhythmic drugs if we can demonstrate that specific targets might be key mediators of obesity-related malignant VT? This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.